STXS - Stereotaxis Inc Stock Price, Fair Value and News

2.10USD+0.01 (+0.48%)Delayed

Market Summary

USD2.10+0.01

Delayed

0.48%

STXS Stock Price

View Fullscreen

STXS RSI Chart

STXS Valuation

Market Cap

173.6M

Price/Earnings (Trailing)

-8.59

Price/Sales (Trailing)

6.4

Price/Free Cashflow

-19.99

STXS Price/Sales (Trailing)

STXS Profitability

Operating Margin

55.16%

Return on Equity

-138.7%

Return on Assets

-51.21%

Free Cashflow Yield

-5%

STXS Fundamentals

STXS Revenue

Revenue (TTM)

27.1M

Rev. Growth (Yr)

5.07%

Rev. Growth (Qtr)

50.71%

STXS Earnings

Earnings (TTM)

-20.2M

Earnings Growth (Yr)

9.52%

Earnings Growth (Qtr)

4.01%

Breaking Down STXS Revenue

Last 7 days

-3.7%

Last 30 days

-18.6%

Last 90 days

-25%

Trailing 12 Months

24.3%

How does STXS drawdown profile look like?

STXS Financial Health

Current Ratio

2.43

Debt/Equity

0.02

Debt/Cashflow

-35.64

STXS Investor Care

Shares Dilution (1Y)

2.44%

Diluted EPS (TTM)

-0.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	27.1M	0	0	0
2023	27.7M	29.4M	29.5M	26.8M
2022	33.4M	30.5M	29.1M	28.1M
2021	29.5M	33.2M	33.6M	35.0M
2020	27.6M	26.2M	26.7M	26.6M
2019	29.0M	28.6M	29.3M	28.9M
2018	30.5M	0	29.9M	29.3M
2017	30.5M	31.1M	30.9M	31.1M
2016	36.8M	35.0M	34.1M	32.2M
2015	36.2M	37.8M	38.2M	37.7M
2014	38.0M	36.3M	34.3M	35.0M
2013	42.7M	41.9M	41.2M	38.0M
2012	44.0M	43.0M	46.0M	46.6M
2011	53.7M	50.2M	44.9M	42.0M
2010	0	52.1M	53.1M	54.1M
2009	0	0	0	51.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Stereotaxis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	menawat arun swarup	acquired	-	-	64,935	-
Jan 02, 2024	curet myriam	acquired	-	-	64,935	-
Jan 02, 2024	levin ross b	acquired	-	-	64,935	-
Jan 02, 2024	fischel nathan	acquired	-	-	64,935	-
Jan 02, 2024	benfer david	acquired	-	-	64,935	-
Jan 02, 2024	messey robert j	acquired	-	-	64,935	-
Dec 15, 2023	isaac paul j	bought	19,023	1.72	11,060	-
Nov 30, 2023	isaac paul j	bought	4,380	1.56	2,808	-
Nov 22, 2023	isaac paul j	bought	27.00	1.5	18.00	-
Nov 21, 2023	isaac paul j	bought	9,180	1.53	6,000	-

Which funds bought or sold STXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	77.53	459,635	738,581	-%
May 15, 2024	Squarepoint Ops LLC	new	-	65,177	65,177	-%
May 15, 2024	Lagoda Investment Management, L.P.	added	18.35	4,329,940	9,989,330	6.13%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	898	1,765,810	1,892,870	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	338,677	338,677	-%
May 15, 2024	DAFNA Capital Management LLC	unchanged	-	11,765,300	35,706,200	8.13%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-276,008	-	-%
May 15, 2024	Redmile Group, LLC	reduced	-2.75	2,681,690	8,635,960	0.32%
May 15, 2024	Brevan Howard Capital Management LP	new	-	44,928	44,928	-%
May 15, 2024	Arbiter Partners Capital Management LLC	unchanged	-	2,369,900	7,192,360	9.06%

Are Funds Buying or Selling STXS?

Are funds buying STXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STXS

No. of Funds

Unveiling Stereotaxis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	redmile group, llc	4.2%	3,402,443	SC 13G/A
Feb 14, 2023	redmile group, llc	8.8%	7,097,616	SC 13G/A
Feb 14, 2022	redmile group, llc	9.1%	7,308,325	SC 13G/A
Feb 03, 2022	arbiter partners capital management llc	3.0%	2,208,952	SC 13G/A
Jun 16, 2021	kiani joe e	9.99%	7,540,515	SC 13G
Feb 17, 2021	arbiter partners capital management llc	5.7%	4,208,952	SC 13G/A
Feb 16, 2021	redmile group, llc	9.9%	7,833,765	SC 13G/A
Feb 12, 2021	opaleye management inc.	4.10%	9	SC 13G/A
Feb 14, 2020	opaleye management inc.	6.16%	9	SC 13G/A
Feb 14, 2020	redmile group, llc	9.9%	7,053,462	SC 13G/A

Recent SEC filings of Stereotaxis Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 08, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Stereotaxis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Stereotaxis Inc News

Latest updates

Stereotaxis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	50.7%	6,880	4,565	7,799	7,859	6,548	7,301	7,657	6,152	7,037	8,241	9,106	9,051	8,623	6,825	8,704	5,345	5,756	6,893	8,202	6,798	7,010
Cost Of Revenue	59.5%	2,914	1,827	3,740	3,672	2,672	2,992	3,090	1,482	2,113	2,291	4,372	2,519	2,607	1,603	4,025	1,085	951	1,745	1,832	1,147	1,412
Gross Profit	44.9%	3,966	2,738	4,059	4,187	3,876	4,309	4,567	4,670	4,924	5,950	4,734	6,532	6,016	5,222	4,678	4,260	4,805	5,147	6,370	5,651	5,598
Operating Expenses	8.3%	8,712	8,042	9,698	9,464	9,495	8,765	9,619	9,849	9,013	9,299	9,354	9,923	7,544	6,399	6,241	6,182	6,857	6,334	6,411	7,110	7,737
S&GA Expenses	7.6%	3,003	2,791	3,097	3,340	3,148	2,989	3,111	3,279	2,946	3,046	2,910	3,045	2,947	2,898	2,823	2,542	2,915	3,066	3,121	3,237	3,310
R&D Expenses	1.4%	2,243	2,212	2,668	2,647	2,746	2,400	2,818	2,893	2,447	2,615	2,500	2,717	2,367	2,098	1,953	1,977	2,109	1,616	1,751	2,695	2,959
Interest Expenses	-8.4%	239	261	270	293	272	318	135	45.00	3.00	-5.50	1.00	-3.00	-4.00	-4.24	-9.93	567*	81.00	102	85.00	32.00	17.00
Net Income	4.0%	-4,838	-5,040	-5,369	-4,957	-5,347	-4,154	-4,917	-5,134	-4,086	-3,354	-4,619	-1,211	-1,532	-1,180	-1,572	-1,921	-1,971	-1,084	44.00	-1,427	-2,122
Net Income Margin	3.7%	-0.75*	-0.77*	-0.67*	-0.66*	-0.71*	-0.65*	-0.60*	-0.56*	-0.40*	-0.31*	-0.25*	-0.17*	-	-	-	-	-	-	-	-	-
Free Cashflow	3.8%	-2,346	-2,439	-967	-2,931	-2,802	-2,552	-2,533	-1,137	-2,193	-1,219	-1,456	34.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.9%	39.00	42.00	45.00	48.00	51.00	53.00	56.00	57.00	57.00	61.00	62.00	57.00	59.00	55.00	57.00	57.00	42.00	44.00	43.00	21.00	22.00
Current Assets	-6.2%	31.00	33.00	36.00	39.00	41.00	43.00	46.00	47.00	47.00	51.00	53.00	55.00	57.00	53.00	54.00	53.00	37.00	39.00	38.00	16.00	16.00
Cash Equivalents	-7.9%	18.00	20.00	22.00	23.00	6.00	9.00	31.00	33.00	35.00	40.00	40.00	42.00	42.00	44.00	44.00	44.00	28.00	30.00	32.00	8.00	9.00
Inventory	-2.1%	8.00	8.00	7.00	8.00	9.00	8.00	8.00	8.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	5.00	3.00	2.00	2.00	2.00	1.00
Net PPE	-4.2%	3.00	3.00	3.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-2.8%	19.00	20.00	20.00	21.00	21.00	21.00	23.00	21.00	20.00	22.00	22.00	15.00	18.00	15.00	17.00	16.00	14.00	15.00	15.00	17.00	17.00
Current Liabilities	-3.0%	13.00	13.00	13.00	14.00	14.00	14.00	16.00	14.00	11.00	13.00	14.00	13.00	17.00	14.00	13.00	14.00	12.00	12.00	11.00	13.00	12.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	0.00	2.00	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	2.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	2.00	-	-	-	-	-	-
Shareholder's Equity	-10.9%	15.00	16.00	19.00	21.00	24.00	26.00	28.00	30.00	32.00	34.00	35.00	36.00	35.00	35.00	35.00	36.00	22.00	23.00	23.00	-	-
Retained Earnings	-0.8%	-542	-537	-532	-527	-522	-516	-512	-507	-502	-498	-495	-490	-489	-487	-486	-485	-483	-481	-480	-480	-478
Additional Paid-In Capital	0.5%	557	554	551	549	546	543	541	538	535	533	530	527	524	523	522	521	505	504	503	479	478
Shares Outstanding	3.4%	83.00	81.00	80.00	79.00	77.00	76.00	76.00	76.00	76.00	76.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	101	-	-	-	111	-	-	-	578	-	-	-	234	-	-	-	112	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.8%	-2,346	-2,439	-967	-2,931	-2,802	-2,552	-2,533	-1,137	-2,193	-1,219	-1,456	34.00	-305	308	-482	-1,170	-2,165	-1,914	-405	-518	-1,776
Share Based Compensation	-1.8%	2,589	2,636	2,673	2,659	2,655	2,670	2,695	2,697	2,514	2,610	2,597	2,785	1,371	756	756	935	722	431	426	325	148
Cashflow From Investing	-	-	-	-10.00	20,124	-349	-20,085	-205	-650	-1,154	-1,196	-51.00	-116	-34.00	-	-	-	-	-13.65	-6.00	-	-9.83
Cashflow From Financing	15.4%	30.00	26.00	25.00	-26.00	56.00	61.00	48.00	57.00	54.00	11.00	134	120	282	36.00	73.00	17,223	8.00	460	23,590	-49.96	32.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STXS Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 6,880	$ 6,548
Cost of revenue:
Total cost of revenue	2,914	2,672
Gross margin	3,966	3,876
Operating expenses:
Research and development	2,243	2,746
Sales and marketing	3,003	3,148
General and administrative	3,466	3,601
Total operating expenses	8,712	9,495
Operating loss	(4,746)	(5,619)
Interest income, net	239	272
Net loss	(4,507)	(5,347)
Cumulative dividend on convertible preferred stock	(331)	(331)
Net loss attributable to common stockholders	$ (4,838)	$ (5,678)
Net loss per share attributable to common stockholders:
Basic	$ (0.06)	$ (0.07)
Diluted	$ (0.06)	$ (0.07)
Weighted average number of common shares and equivalents:
Basic	83,476,498	76,500,965
Diluted	83,476,498	76,500,965
Systems [Member]
Revenue:
Total revenue	$ 2,612	$ 1,821
Cost of revenue:
Total cost of revenue	1,900	1,697
Disposables Service and Accessories [Member]
Revenue:
Total revenue	4,268	4,727
Cost of revenue:
Total cost of revenue	$ 1,014	$ 975

STXS Balance Sheet

2024-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 17,633	$ 19,818
Restricted cash - current	525	525
Accounts receivable, net of allowance of $609 and $672 at 2024 and 2023, respectively	3,953	3,822
Inventories, net	8,252	8,426
Prepaid expenses and other current assets	845	676
Total current assets	31,208	33,267
Property and equipment, net	3,164	3,304
Restricted cash	88	219
Operating lease right-of-use assets	4,876	4,982
Prepaid and other non-current assets	116	137
Total assets	39,452	41,909
Current liabilities:
Accounts payable	3,307	3,190
Accrued liabilities	3,164	2,972
Deferred revenue	5,938	6,657
Current portion of operating lease liabilities	443	428
Total current liabilities	12,852	13,247
Long-term deferred revenue	1,581	1,637
Operating lease liabilities	4,945	5,062
Other liabilities	43	43
Total liabilities	19,421	19,989
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,908 and 22,358 shares outstanding at 2024 and 2023	5,464	5,577
Stockholders’ equity:
Common stock, par value $0.001; 300,000,000 shares authorized, 82,132,777 and 80,949,697 shares issued at 2024 and 2023, respectively	82	81
Additional paid in capital	556,878	554,148
Treasury stock, 4,015 shares at 2024 and 2023	(206)	(206)
Accumulated deficit	(542,187)	(537,680)
Total stockholders’ equity	14,567	16,343
Total liabilities and stockholders’ equity	$ 39,452	$ 41,909

About Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

CEO	Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA
WEBSITE	stereotaxis.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	130

Stereotaxis Inc Frequently Asked Questions

What is the ticker symbol for Stereotaxis Inc? What does STXS stand for in stocks?

STXS is the stock ticker symbol of Stereotaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stereotaxis Inc (STXS)?

As of Fri May 17 2024, market cap of Stereotaxis Inc is 173.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STXS stock?

You can check STXS's fair value in chart for subscribers.

What is the fair value of STXS stock?

You can check STXS's fair value in chart for subscribers. The fair value of Stereotaxis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stereotaxis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stereotaxis Inc a good stock to buy?

The fair value guage provides a quick view whether STXS is over valued or under valued. Whether Stereotaxis Inc is cheap or expensive depends on the assumptions which impact Stereotaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STXS.

What is Stereotaxis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, STXS's PE ratio (Price to Earnings) is -8.59 and Price to Sales (PS) ratio is 6.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Stereotaxis Inc's stock?

In the past 10 years, Stereotaxis Inc has provided -0.056 (multiply by 100 for percentage) rate of return.